All In Biotech

Free tool

FAERS Monitor: Juxtapid

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203858 or its brand name (Juxtapid, Lomitapide Mesylate). Reports on generic versions are filed under their own applications.

Reports

3,782

Serious

1,231

33% of reports

Hospitalization

389

Death reported

94

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea1,076
  • weight decreased844
  • therapy cessation792
  • nausea558
  • abdominal pain upper287
  • abdominal discomfort242
  • flatulence242
  • vomiting219
  • off label use208
  • fatigue206
  • hepatic enzyme increased188
  • drug dose omission184
  • inappropriate schedule of drug administration184
  • constipation169
  • abdominal pain166

Reports by year received

View as table
YearReports
201386
2014551
20151,346
2016316
2017327
2018343
2019169
2020193
2021137
202278
202376
202464
202561
202635

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,377 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
therapy cessationSignal79287.181.966,472
flatulenceSignal24223.821.15,262
weight decreasedSignal84416.915.912,708
hepatic enzyme increasedSignal18815.413.42,514
inappropriate schedule of drug administrationSignal18414.412.52,286
diarrhoeaSignal1,0769.38.88,183
abdominal discomfortSignal2428.07.11,493
abdominal pain upperSignal2877.86.91,698
drug dose omissionSignal1846.25.4802
constipationSignal1694.33.7431
abdominal painSignal1664.03.4370
nauseaSignal5583.93.61,259
vomitingSignal2192.62.3217
fatigue2061.51.332
off label use2081.31.217

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.